Abstract
The heterodimeric transcription factor HIF-1 (hypoxia-inducible factor-1) induces angiogenesis, a process that is aberrantly elevated in cancer. The HIF-1β subunit is constitutively expressed, but the levels of the HIF-1α subunit are robustly regulated, increasing under hypoxic conditions and decreasing in normoxia. These changes result from rapid alterations in the rates of HIF-1α production and degradation. While the regulation of HIF-1α degradation is understood in significant detail, much less is known about the regulation of HIF-1α biosynthesis. Here, we review recent evidence that HIF-1α production is effectively controlled by post-transcriptional mechanisms. We focus on the RNA-binding proteins (RBPs) and the non-coding RNAs that interact with the HIF-1α mRNA and influence its half-life and translation rate. HIF-1α mRNA-binding factors are emerging as promising pharmacological targets to control HIF-1α production selectively and efficiently.
Keywords: Post-transcriptional gene regulation, RNA-binding proteins, microRNA, antisense RNA, IRES
Current Pharmaceutical Design
Title: Factors Interacting with HIF-1α mRNA: Novel Therapeutic Targets
Volume: 15 Issue: 33
Author(s): Stefanie Galban and Myriam Gorospe
Affiliation:
Keywords: Post-transcriptional gene regulation, RNA-binding proteins, microRNA, antisense RNA, IRES
Abstract: The heterodimeric transcription factor HIF-1 (hypoxia-inducible factor-1) induces angiogenesis, a process that is aberrantly elevated in cancer. The HIF-1β subunit is constitutively expressed, but the levels of the HIF-1α subunit are robustly regulated, increasing under hypoxic conditions and decreasing in normoxia. These changes result from rapid alterations in the rates of HIF-1α production and degradation. While the regulation of HIF-1α degradation is understood in significant detail, much less is known about the regulation of HIF-1α biosynthesis. Here, we review recent evidence that HIF-1α production is effectively controlled by post-transcriptional mechanisms. We focus on the RNA-binding proteins (RBPs) and the non-coding RNAs that interact with the HIF-1α mRNA and influence its half-life and translation rate. HIF-1α mRNA-binding factors are emerging as promising pharmacological targets to control HIF-1α production selectively and efficiently.
Export Options
About this article
Cite this article as:
Galban Stefanie and Gorospe Myriam, Factors Interacting with HIF-1α mRNA: Novel Therapeutic Targets, Current Pharmaceutical Design 2009; 15 (33) . https://dx.doi.org/10.2174/138161209789649376
DOI https://dx.doi.org/10.2174/138161209789649376 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System
Current Stem Cell Research & Therapy The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Involvement of the Mitochondrial Benzodiazepine Receptor in Traumatic Brain Injury: Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy
Current Pharmaceutical Design Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Physiological Roles of Neurite Outgrowth Inhibitors in Myelinated Axons of the Central Nervous System – Implications for the Therapeutic Neutralization of Neurite Outgrowth Inhibitors
Current Pharmaceutical Design Patent Selections
Recent Patents on Biotechnology Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets An Overview of Labeled Porphyrin Molecules in Medical Imaging
Recent Patents and Topics on Imaging (Discontinued) Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain
Current Nanoscience Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology The Radio-Sensitizing Effect of Pharmacological Concentration of Ascorbic Acid on Human Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Flavonoids: The Innocuous Agents Offering Protection against Alzheimer’s Disease Through Modulation of Proinflammatory and Apoptotic Pathways
Current Topics in Medicinal Chemistry VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Neurosteroids and Hepatic Encephalopathy: An Update on Possible Pathophysiologic Mechanisms
Current Molecular Pharmacology Matrix Metalloproteinases: Drug Targets for Myocardial Infarction
Current Drug Targets Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design Exploration of (hetero)aryl Derived Thienylchalcones for Antiviral and Anticancer Activities
Medicinal Chemistry New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems
Current Pharmaceutical Design